LAWSON MACARTNEY - 17 Apr 2023 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Director
Signature
/s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol
VKTX
Transactions as of
17 Apr 2023
Net transactions value
-$249,432
Form type
4
Filing time
18 Apr 2023, 19:10:09 UTC
Previous filing
04 Jan 2023
Next filing
24 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $166,288 +20,786 +43% $8.00 68,751 17 Apr 2023 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale $415,720 -20,786 -30% $20.00 47,965 17 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -20,786 -100% $0.000000* 0 17 Apr 2023 Common Stock 20,786 $8.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person.
F2 100% of the shares subject to the option vested on May 26, 2016, the date of the Issuer's first Annual Meeting of Stockholders following the date of grant.